These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 18363524)
21. The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes. Del Rosso JQ; Kircik LH; Zeichner J; Stein Gold L J Drugs Dermatol; 2019 Feb; 18(2s):s100-s107. PubMed ID: 30811153 [TBL] [Abstract][Full Text] [Related]
22. A Guide to Topical Vehicle Formulations. Mayba JN; Gooderham MJ J Cutan Med Surg; 2018; 22(2):207-212. PubMed ID: 29137492 [TBL] [Abstract][Full Text] [Related]
23. Compounding is still appropriate in clinical practice. Thiers BH Dermatol Clin; 1998 Apr; 16(2):329-30. PubMed ID: 9589206 [TBL] [Abstract][Full Text] [Related]
28. Determination of 2-methyl-2,4-pentane diol (hexylene glycol) in the urine of man and rats. JACOBSEN E Acta Pharmacol Toxicol (Copenh); 1958; 14(2):195-206. PubMed ID: 13508273 [No Abstract] [Full Text] [Related]
29. The excretion of hexylene glycol (2-methyl-2,4-pentane diol) in man. JACOBSEN E Acta Pharmacol Toxicol (Copenh); 1958; 14(3):207-13. PubMed ID: 13532730 [No Abstract] [Full Text] [Related]
30. Iatrogenic contact dermatitis and eczematous reactions. Angelini G; Vena GA; Grandolfo M; Mastrolonardo M Clin Dermatol; 1993; 11(4):467-77. PubMed ID: 8124635 [No Abstract] [Full Text] [Related]
31. [Sensitization to topical corticoids in patients with chronic eczema of the legs]. Lazzarini S AMB Rev Assoc Med Bras; 1979 Apr; 25(4):118-20. PubMed ID: 315593 [No Abstract] [Full Text] [Related]
32. Allergic contact dermatitis to preservatives in topical medicaments. Skinner SL; Marks JG Am J Contact Dermat; 1998 Dec; 9(4):199-201. PubMed ID: 9810018 [TBL] [Abstract][Full Text] [Related]
34. [Topical drug vehicles--influence of galenics in the therapy of atopic eczema]. Daniels R Med Monatsschr Pharm; 2008 Apr; 31(4):139-43. PubMed ID: 18497245 [TBL] [Abstract][Full Text] [Related]
35. Ionic liquids as ingredients in topical drug delivery systems. Dobler D; Schmidts T; Klingenhöfer I; Runkel F Int J Pharm; 2013 Jan; 441(1-2):620-7. PubMed ID: 23123180 [TBL] [Abstract][Full Text] [Related]
36. Preparation and in vitro/in vivo evaluation of antimicrobial ocular in situ gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis. Saher O; Ghorab DM; Mursi NM Pharm Dev Technol; 2016 Aug; 21(5):600-10. PubMed ID: 25886078 [TBL] [Abstract][Full Text] [Related]
37. Polymeric vehicles for topical delivery and related analytical methods. Cho HK; Cho JH; Jeong SH; Cho DC; Yeum JH; Cheong IW Arch Pharm Res; 2014 Apr; 37(4):423-34. PubMed ID: 24643380 [TBL] [Abstract][Full Text] [Related]
38. Comparison of objective and sensory skin irritations of several cosmetic preservatives. Lee E; An S; Choi D; Moon S; Chang I Contact Dermatitis; 2007 Mar; 56(3):131-6. PubMed ID: 17295686 [TBL] [Abstract][Full Text] [Related]